Disabling glycosylation at these two sites can reduce glycolysis and improve T cell-mediated anti-tumor immune responses, respectively, and works synergistically with PD-L1 monoclonal antibody treatment, thereby presenting an innovative approach to colorectal cancer therapy [48]. Here, CD274 is linked to colorectal cancer.